American Medical Systems Holdings, Inc. and Caldera Medical, Inc. today announced that they have entered into a settlement and cross-license agreement. AMS filed suit against Caldera in November 2005 claiming that Caldera infringed on certain patents related to treating stress urinary incontinence. The companies have entered into a restricted, royalty bearing cross-license agreement that covers a broad intellectual property portfolio of both incontinence and prolapse technologies, allowing each company to focus upon providing solutions to patients. The cross-license restriction relates to the ability for the companies to protect the uniqueness of their products. AMS has subsequently dismissed the suit.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Cerapedics Earns Premarket Approval for Bone Graft
The premarket approval allows the labeling to state that clinical data showed statistical superiority over autologous bone graft was maintained in its second-year follow-up.
Reblozyl Earns FDA’s First Approval for Rare Blood Disorder
Reblozyl was previously granted both fast track and orphan drug designations.
